Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 15/11/2022
• Auteurs : Marine BaronKarim LabrecheAmira BouzidiMarianne VeyriNathalie DésiréVéronique LeblondFlorence CouletPierre-Yves BoelleFatou Seck ThiamDamien Roos-WeilFrédéric CharlotteFrederic DaviElsa PoullotAlice RousseauCorinne HaiounJean-Philippe SpanoBrigitte AutranChoquet SylvainAmélie Guihot
• Organismes : CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche Saint-Antoine Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche des Cordeliers Hôpital Henri Mondor Centre d'Immunologie et des Maladies Infectieuses CHU Pitié-Salpêtrière [AP-HP] Hôpital Henri Mondor Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses CHU Pitié-Salpêtrière [AP-HP]
• Publié dans Blood le 28/10/2020

---

Résumé : Non-hodgkin lymphomas (NHL) are among the most common and fatal cancers in HIV-infected patients and transplant recipients. They are frequently associated with the Epstein Barr Virus (EBV) and a central nervous system (CNS) localization. Cancers neoantigens derived from the somatic tumor variants are a key factor of anti-tumor activity and response to immunotherapies, but the immunogenomics and tumor microenvironment (TME) characteristics of NHL from immunodeficient (ID) patients are lacking. We hypothesized they might be influenced by the low immunological pressure, the viral stimulation and/or the immune-privileged site. We report the comprehensive and prospective study of the tumor mutational burden (TMB), numbers of tumor neoepitopes, neoepitopes specific T cell responses and TME in ID patients, according to the EBV status, the immune status and the disease localization. Consecutive HIV-infected patients or transplant recipients with treatment-naïve NHL were included and compared with immunocompetent patients with diffuse large B-cell lymphomas (DLBCL). A whole exome sequencing (WES) was carried out in parallel on tumor and on PBMC for TMB assessment and a whole genome RNA sequencing was performed on frozen tumor biopsies. The neoepitopes derived from the somatic tumor variants (called in WES and RNAseq data) were predicted in silico using a bioinformatic pipeline including pVACseq and NetMHC and filtered according to: VAF≥10%, gene expression≥1 TPM and affinity binding score ≤500 nM. Neoepitopes specific T cell responses were assessed by ELISPOT assays after a 10 days PBMC co-culture with peptides from the Top 50 best predicted autologous neoepitopes (positivity defined as spot forming cells >50/106 cells). For the TME study, the profiling of cell type abundance and the T-cell receptor (TCR) sequencing were performed with deconvolution tools (EPIC) and MiXCR respectively. All statistical tests used R. Sixty-seven patients were included so far: 33 post-transplant lymphoproliferative disorders (PTLD) and 16 HIV-positive NHL, 70% of whom having DLBCL, compared to 18 immunocompetent (IC)-DLBCL. Diseases were systemic in 73% and localized in CNS in 27% cases. The median age was 58 years (range 21-85) and 70% were male. Immuno-molecular data are available for 57 patients so far. The TMB was 3.7/Mb for all patients but was lower in EBV-positive NHL (2.7/Mb) compared to the negative ones (4/Mb) (p=0.012, t-test) (Fig 1) without difference according to the ID status. The overall median number of neoepitopes per tumor predicted from the non-immunoglobulin (Ig) variants was 113 (range 11-720) but was lower in EBV-positive NHL (49 vs 243, p= 0.04, t-test), correlating with the TMB (r=0.8, p<0.0001). Most neoepitopes were MHC-class II restricted (ratio MHC-class II/ MHC- class I= 4.1) independently of the EBV status. The median number of neoepitopes predicted from the Ig heavy chain (IgH) genes was 17.5 (range, 6-36) with a MHC-class II/MHC-class I ratio of 1.4. Neoepitopes specific T cell responses were detectable among 71% cases out of 14 patients tested so far, independently of ID status or CNS localization (Fig 2). All 3 positive responses against Ig-derived neoepitopes out of 5 tested cases were directed against the IgH, MHC-class II restricted and immunodominant compared to those against the non-Ig neoepitopes. There was no shared immunogenic neoepitopes between patients. The TME study showed a higher frequency of CD4+ and CD8+ T cells mean frequency in EBV-positive compared to EBV-negative NHL (11% vs 4% and 10% vs 2% respectively, p<0.03).The intra-tumoral TCR repertoire distribution was mostly polyclonal with a median frequency of dominant clones of 8% (range 1-61) and a lower repertoire diversity, assessed on the ratio of clonotypes number/ total TCR-β reads number, in EBV-positive NHL (29) than in EBV-negative ones (37) (p=0.02), without difference according to the immune status. Our data demonstrate that both immunogenomics and TME of NHL from immuno-compromized patients are preferentially influenced by the EBV status, with lower numbers of tumor neoepitopes correlating with lower TMB, and a lower intra-tumoral TCR diversity in EBV-positive versus EBV-negative NHL. We further demonstrated that anti-tumor immune responses can be mounted despite ID status or CNS localization, especially against MHC-class II presented Ig-variants, and might be targeted for therapeutic strategies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 14/11/2022
• Auteurs : Michael LevrautSabine Laurent-ChabalierXavier AyrignacKévin BigautManon RivalSanae SqualliHélène ZéphirTifanie AlbertoJean-David PekarJonathan CironDamien BiottiBénédicte Puissant-LubranoJean-Philippe CamdessanchéYannick TholanceOlivier CasezBertrand ToussaintJeanne MarionThibault MoreauDaniela LakomyAudrey ThomassetElisabeth MaillartDelphine SterlinAude MauroussetAuriane RocherDavid-Axel LaplaudEdith Bigot-CorbelPierre-Olivier BerthoJean PelletierJoseph BoucrautPierre LabaugeThierry VincentJérôme de SèzeIsabelle JahnBarbara Seitz-PolskiEric ThouvenotChristine Lebrun-Frénay
• Organismes : Université Côte d'Azur - Faculté de Médecine Unité de Recherche Clinique Côte d’Azur Centre Hospitalier Universitaire de Nîmes Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Hôpitaux Universitaires de Strasbourg UR2CA - PIN - Douleur, Innovation & Neuromodulation Laboratoire de Biochimie [CHRU Nîmes] Département de neurologie [Lille] Département de neurologie [Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Hospitalier Universitaire de Toulouse Pôle Neurosciences [CHU Toulouse] Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Hospitalier Universitaire de Toulouse Institut Fédératif de Biologie (IFB) Institut Toulousain des Maladies Infectieuses et Inflammatoires Service de Neurologie [CHU de Saint-Étienne] Institut NeuroMyoGène Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire [CHU Grenoble] Translational microbial Evolution and Engineering Centre Hospitalier Universitaire [CHU Grenoble] Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire Centre d'épidémiologie des populations Service de Biochimie [CHU de Dijon] Service de Biochimie [CHU de Dijon] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Trousseau [Tours] CHU Trousseau [Tours] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 5 : Neuroinflammation, mechanisms, therapeutic options (NEMO) Laboratoire de Biochimie [CHU Nantes] Hôpital Guillaume-et-René-Laennec [Saint-Herblain] Département de Biochimie [CHU Nantes] Hôpital de la Timone [CHU - APHM] Aix Marseille Université Hôpital de la Conception [CHU - APHM] Institut de Neurosciences des Systèmes Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Hôpital Gui de Chauliac [CHU Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] CIC Strasbourg Centre Hospitalier Universitaire [Strasbourg] Laboratoire Immunologie [Nice] Institut de Génomique Fonctionnelle Service de Neurologie [CHU Nice]
• Publié dans Neurology Neuroimmunology & Neuroinflammation le 28/10/2020

---

Résumé : Background and Objectives Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our objectives were to (1) determine diagnostic performances of CSF KFLC, KFLC index, and KFLC intrathecal fraction (IF) threshold values that allow us to separate MS from different CNS disorder control populations and compare them with oligoclonal bands' (OCB) performances and (2) to identify independent factors associated with KFLC quantification in MS. Methods We conducted a retrospective multicenter study involving 13 French MS centers. Patients were included if they had a noninfectious and nontumoral CNS disorder, eligible data concerning CSF and serum KFLC, albumin, and OCB. Patients were classified into 4 groups according to their diagnosis: MS, clinically isolated syndrome (CIS), other inflammatory CNS disorders (OIND), and noninflammatory CNS disorder controls (NINDC). Results One thousand six hundred twenty-one patients were analyzed (675 MS, 90 CIS, 297 OIND, and 559 NINDC). KFLC index and KFLC IF had similar performances in diagnosing MS from nonselected controls and OIND ( p = 0.123 and p = 0.991 for area under the curve [AUC] comparisons) and performed better than CSF KFLC ( p < 0.001 for all AUC comparisons). A KFLC index of 8.92 best separated MS/CIS from the entire nonselected control population, with better performances than OCB ( p < 0.001 for AUC comparison). A KFLC index of 11.56 best separated MS from OIND, with similar performances than OCB ( p = 0.065). In the multivariate analysis model, female gender ( p = 0.003), young age ( p = 0.013), and evidence of disease activity ( p < 0.001) were independent factors associated with high KFLC index values in patients with MS, whereas MS phenotype, immune-modifying treatment use at sampling, and the FLC analyzer type did not influence KFLC index. Discussion KFLC biomarkers are efficient tools to separate patients with MS from controls, even when compared with other patients with CNS autoimmune disorder. Given these results, we suggest using KFLC index or KFLC IF as a criterion to diagnose MS. Classification of Evidence This study provides Class III evidence that KFLC index or IF can be used to differentiate patients with MS from nonselected controls and from patients with other autoimmune CNS disorders.

---

Fichiers liés : e200049.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/11/2022
• Auteurs : Pierre-Antoine ThouveninArwa DabbechMing JiangAbdullah AbdulazizJean-Philippe ThiranAdrian JacksonYves Wiaux
• Organismes : Centrale Lille Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 Heriot-Watt University [Edinburgh] Xidian University Heriot-Watt University [Edinburgh] Ecole Polytechnique Fédérale de Lausanne EPCC [Edinburgh] Heriot-Watt University [Edinburgh]
• Publié dans Monthly Notices of the Royal Astronomical Society le 30/10/2020

---

Résumé : Abstract In a companion paper, a faceted wideband imaging technique for radio interferometry, dubbed Faceted HyperSARA, has been introduced and validated on synthetic data. Building on the recent HyperSARA approach, Faceted HyperSARA leverages the splitting functionality inherent to the underlying primal-dual forward-backward algorithm to decompose the image reconstruction over multiple spatio-spectral facets. The approach allows complex regularization to be injected into the imaging process while providing additional parallelization flexibility compared to HyperSARA. The present paper introduces new algorithm functionalities to address real datasets, implemented as part of a fully fledged MATLAB imaging library made available on https://basp-group.github.io/Puri-Psi/Github. A large scale proof-of-concept is proposed to validate Faceted HyperSARA in a new data and parameter scale regime, compared to the state-of-the-art. The reconstruction of a 15 GB wideband image of Cyg A from 7.4 GB of VLA data is considered, utilizing 1440 CPU cores on a HPC system for about 9 hours. The conducted experiments illustrate the reconstruction performance of the proposed approach on real data, exploiting new functionalities to leverage known direction-dependent effects (DDEs), for an accurate model of the measurement operator, and an effective noise level accounting for imperfect calibration. They also demonstrate that, when combined with a further dimensionality reduction functionality, Faceted HyperSARA enables the recovery of a 3.6 GB image of Cyg A from the same data using only 91 CPU cores for 39 hours. In this setting, the proposed approach is shown to provide a superior reconstruction quality compared to the state-of-the-art wideband CLEAN-based algorithm of the WSClean software.

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2022
• Auteurs : Thomas BachelotPaul-Henri CottuSylvie ChabaudFlorence DalencDjelila AllouacheSuzette DelalogeJean-Philippe JacquinJulien GrenierLaurence Venat BouvetApurna JegannathenMario CamponeFrancesco del PianoMarc DebledAnne-Claire Hardy-BessardSylvie GiacchettiMarie-Ange Mouret-ReynierPhilippe BarthelemyLaure KaluzinskiAudrey MailliezÉric LegouffeMatthew SephtonJudith BlissJean-Luc CanonFrédérique Penault-LlorcaJerome LemonnierDavid CameronFabrice André
• Organismes : Centre Léon Bérard [Lyon] Department of Medical Oncology, Institut Curie, Paris 75248, France Centre Léon Bérard [Lyon] Oncopole Claudius Regaud Institut Universitaire du Cancer de Toulouse - Oncopole Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Service Oncologie Médicale [Saint Priest en Jarez] Laboratoire de Biologie du Développement Institut de Cancérologie de l'Ouest [Angers/Nantes] Institut Bergonié [Bordeaux] Centre Armoricain de Radiothérapie, d'Imagerie médicale et d'Oncologie [Plérin, Saint-Brieuc] Hôpital Saint-Louis Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand] ChemBioPharm Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Service d'hématologie et oncologie médicale
• Publié dans Journal of Clinical Oncology le 01/11/2020

---

Résumé : PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor–resistant metastatic breast cancer. However, the benefit of adding everolimus to ET in the adjuvant setting in early breast cancer is unknown. PATIENTS AND METHODS In this randomized double-blind phase III study, women with high-risk, hormone receptor–positive, human epidermal growth factor receptor 2–negative primary breast cancer were randomly assigned to everolimus or placebo for 2 years combined with standard ET. Stratification factors included ET agent, receipt of neoadjuvant versus adjuvant chemotherapy, progesterone receptor status, duration of ET before random assignment, and lymph node involvement. The primary end point was disease-free survival (DFS). The trial is registered with ClinicalTrials.gov (identifier: NCT01805271 ). RESULTS Between June 2013 and March 2020, 1,278 patients were randomly allocated to receive everolimus or placebo. At the first interim analysis, the trial was stopped for futility and a full analysis undertaken once data snapshot complete. One hundred forty-seven patients have had a DFS event reported and at 3 years, DFS did not differ between patients who received ET plus everolimus (88% [95% CI, 85 to 91]) or ET plus placebo (89% [95% CI, 86 to 91; hazard ratio, 0.95; 95% CI, 0.69 to 1.32; P = .77]). Grade ≥ 3 adverse events were reported in 22.9% of patients (29.9% with everolimus v 15.9% with placebo, P < .001). 53.4% everolimus-treated patients permanently discontinued experimental treatment early compared with placebo-treated 22.3%. CONCLUSION Among high-risk patients, everolimus added to adjuvant ET did not improve DFS. Tolerability was a concern, with more than half of patients stopping everolimus before study completion. Everolimus cannot be recommended in the adjuvant setting.

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 10/11/2022
• Auteurs : Adam Abed AbudBabak AbiRoberto AcciarriMario AceroMarcio AdamesGeorge AdamovMark AdamowskiDavid AdamsMarco AdinolfiCris AdrianoAntoni AduszkiewiczJessica AguilarZubayer AhmadJhanzeb AhmedBenjamin AimardFaiza AkbarKyle AllisonSaul Alonso MonsalveMunera AlrashedChristoph AltAndrew AltonRodrigo AlvarezPablo AmedoJohn AndersonDiego Andrade AldanaCostas AndreopoulosMirco AndreottiMichael P. AndrewsFenompanirina AndrianalaSofia AndringaNikolay AnfimovWallison Luiz Anicézio CampanelliArtur AnkowskiMarcelo AntoniassiMaria AntonovaAlexander AntoshkinStefan AntuschAlfredo Aranda-FernandezLuciano ArellanoLukas ArnoldManuel ArroyaveJonathan AsaadiLily AsquithAdam AurisanoVladimir AushevDario AutieroMarco Alberto Ayala-TorresFarrukh AzfarAshley BackHenning BackJ.J. BackIuri BagaturiaLinda BagbyNikita BalashovSupraja BalasubramanianPierre BaldiBruce BallerBindu BambahFernando BaraoGabriela BarenboimG.J. BarkerWayne BarkhouseChristopher BarnesGiles BarrJuan Barranco MonarcaAdilson BarrosNuno BarrosJoshua BarrowAnastasia Basharina-FreshvilleAmit BashyalVincent BasqueCharlie BatchelorJames BattatFederico BattistiFatih BayMaria BazettoJosé Luis Bazo AlbaJ.F. BeacomEdouard BechetoilleBiswaranjan BeheraEwerton BelchiorLeo BellantoniGiorgio BellettiniVincenzo BelliniOlga BeltramelloNektarios BenekosCarlos Benitez MontielDouglas BenjaminFrancisco Bento NevesJoshua BergerSophie BerkmanPaolo BernardiniRoman BernerAndrea BersaniSergio BertolucciMinerba BetancourtAmalia Betancur RodríguezAdrian BevanYashwanth BezawadaAnibal BezerraThiago BezerraJay BhambureAkhil BhardwajVipin BhatnagarMaharnab BhattacharjeeDevesh BhattaraiShyam BhullerBipul BhuyanSimone BiagiJianming BianMatteo BiassoniKurt BieryBurak BilkiMary BishaiValeria BisignaniAlexander BitadzeAndrew BlakeF.D. BlaszczykGerald BlazeyDylan BlendEdward BlucherJan BoissevainAndrey BobyshevSara BolognesiTimothy BoltonLuca BombenMaurizio BonesiniCesar Bonilla-DiazFiliberto BoniniAlexander BoothFatma BoranStefania BordoniAran BorkumNilay BostanPetr BourDaniel BoydenJuraj BracinikDavide BragaDominic BrailsfordAntonio BrancaAndrew BrandtJohan BremerChristopher BrewStephen BriceClaudia BrizzolariCarl BrombergJim BrookeAlan BrossGiulia BrunettiMaria BrunettiNorman BuchananHoward BuddJonas BuergiGian Caceres VeraIrene CagnoliTejin CaiDavide CaiuloRoberto CalabresePaolo CalafiuraJacob CalcuttMarius CalinLivio CaliversSteven CalvezEnrique CalvoAlessio CaminataDavid CaratelliDaniel CarberJ.C. CarcellerGabriella CariniBruno CarlusMateus CarneiroPaolo CarnitiIvan Caro TerrazasHector CarranzaNicholas CarraraLauren CarrollThomas CarrollJavier Castaño ForeroAndrés CastilloErika Catano-MurCarla CattadoriFabien CavalierGiuseppe CavallaroFlavio CavannaSandro CentroGiuseppe CeratiAlberto CervelliAnselmo Cervera VillanuevaKaustav ChakrabortyMichel ChalifourAndrew ChappellEtienne ChardonnetNikolas CharitonidisAnimesh ChatterjeeSubhasish ChattopadhyayHucheng ChenMu-Chun ChenYifan ChenZheyang ChenZachary Chen-WishartYoolim CheonDaniel CherdackCheng-Yi ChiSam ChildressRobert ChircoAna ChiriacescuNamitha ChitirasreemadamKihyeon ChoSarah ChoateDavid ChokheliP.S. ChongBarnali ChowdhuryAnne ChristensenDavid ChristianGeorgios ChristodoulouArtem ChukanovMoses ChungEric ChurchValentina CiceroPeter ClarkeGordon ClineThomas CoanAlfredo CoccoJ.A.B. CoelhoJohann CollotErin ConleyJanet M. ConradMark ConverySimone CopelloPaolo CovaLucien CremaldiLinda CremonesiJ.I. Crespo-AnadónMichael CrislerEsteban CristaldoJason CrnkovicRyan CrossAndrew CuddClara CuestaYanou CuiDavid CussansOlivia DalagerRicardo DallavalleHelio da MottaZubair DarLeonardo da Silva PeresClaire DavidQuentin DavidGavin DaviesStefano DaviniJaime DawsonKaushik DeShruti DePaul DebbinsIsabelle de BonisM. Patrick DecowskiAndre de GouveaPedro de HolandaI.L. de Icaza AstizAlexander DeistingPaul de JongAndres de la TorreAlain DelbartVeronica de LeoDavid DelepineMaritza DelgadoAndrea Dell'AcquaNicola DelmontePatrick de LurgioPhilip DemarJ.R. de Mello NetoDavid DemuthSteve DennisChris DenshamGrzegorz DeptuchAlbert de RoeckValentina de RomeriGreg de SouzaJ.P. DetjeRitu DeviRanjan DharmapalanMarco DiasJorge S. DiazFelix DíazFrancesco Di CapuaAntonio Di DomenicoSergio Di DomizioLetizia Di GiulioPengfei DingLea Di NotoCarla DistefanoRichard DiurbaMilind DiwanZelimir DjurcicDionisio DoeringStephen DolanFurkan DolekMichelle J. DolinskiLaura DomineSimone DonatiYann DononSteven DoranDaniel DouglasAngelo DragoneFrancois DrielsmaLaura Cristina DuarteDominique DuchesneauKirsty DuffyKatherine DugasPatrick DunneBhaskar DuttaHongyue DuyangOlexiy DvornikovDaniel A. DwyerAlexandre S. DyshkantMichael EadsAntony EarleDaniel EdmundsJonathan EischLorenz EmbergerPanagiotis EnglezosAntonio EreditatoTyler ErjavecCarlos O. EscobarJustin EvansErin EwartAnthony EzeribeKevin FaheyLukas FajtAndrea FalconeMattia FaniChristian FarneseYasaman FarzanDmitry FedoseevJulian FelixYue FengEnrique Fernandez-MartinezFederico FerraroLaura FieldsPeter FilipAmy FilkinsFrank FilthautRobert FineGiuliana FiorilloMassimiliano FioriniVincent FischerR.S. FitzpatrickWill FlanaganBonnie FlemingRobert FlightSam FogartyWill ForemanJack FowlerJiri FrancDomenico FrancoJohn FreemanJulian FreestoneJack FriedAlex FriedlandStu FuessI.K. FuricKrzysztof FurmanAndrew FurmanskiAlessandro GabrielliA.M. GagoHugh GallagherAlexandre GallasAna Gallego-RosNiccolo GalliceVyacheslav GalymovEnrico GamberiniTrevor GambleFrancisco GanacimRaj GandhiSudeshna GangulyFan GaoShanshan GaoDiego Garcia-GamezMiguel García-PerisSteven GardinerDan GastlerAnja GauchJean-Luc GauvreauPaolo GauzziGuanqun GeNicolas GeffroyBruno GelliAdamo GendottiStephen GentZahra Ghorbani-MoghaddamPaola GiammariaTommaso GiammariaNico GiangiacomiDaniele GibinInes Gil-BotellaSean GilliganAntonio GioiosaClaude GirerdAnjan Kumar GiriDario GnaniOlga GogotaMichael GoldSowjanya GollapinniKeith GollwitzerRicardo GomesLaura Vanessa Gomez BermeoL.S. Gomez FajardoFrancesco GonnellaDiego Gonzalez-DiazManuel Gonzalez-LopezMaury GoodmanOwen GoodwinSrubabati GoswamiClaudio GottiEvgueni GoudzovskiCarl GraceRik GranEverardo GranadosPierre GrangerChristopher GrantDiego GratieriPatrick GreenStephen GreenbergLeland GreenlerJoel GreerJean-Louis GrenardClark GriffithFlorian GroetschlaMicah GrohKatarzyna GrzelakWenqiang GuElena GuardincerriVictor GuarinoMarco GuariseRoxanne GuenetteEric GuerardMarco GuerzoniDaniele GuffantiAlberto GuglielmiBing GuoAseem GuptaVikas GuptaK.K. GuthikondaPawel GuzowskiMarcelo GuzzoSunwoo GwonChang Hyon HaKevin HaafAlec HabigHaleh HadavandRoger HaenniLee HagamanAlan HahnJames HaistonPhilip Hamacher-BaumannThomas HamernikPhilip HamiltonJiyeon HanDeborah HarrisJeffrey HartnellTrevor HartnettJohn HartonTakyua HasegawaCiaran HasnipRobert HatcherKaleb HatfieldAthanasios HatzikoutelisChristopher HayesKaren HayrapetyanJonathan HaysEric HazenMuyuan HeAnne HeaveyKarsten HeegerJaret HeiseSarah HenryMiguel Angel Hernandez MorquechoKenneth HernerV. HewesChristopher HilgenbergTony HillStephen HillierAlexander HimmelElise HinkleLuciana HirschJames HoffAnna HolinEric HoppeGlenn Horton-SmithMatheus HostertAdrien HourlierBruce HowardRyan HowellJaime Hoyos BarriosIvana HristovaMaxine HronekJunying HuangRoger HuangZachary HulcherGregory IlesNikolina IlicAntoniu IliescuRobert IllingworthGianfranco IngrattaAra IoannisianBurke IrwinLarry IsenhowerMarcelo Ismerio OliveiraRan ItayChristopher JacksonVivek JainEric JamesWooyoung JangBenjamin JargowskyFilip JedinyDeepika JenaYu Seon JeongCésar Jesús-VallsXiangpan JiJunjie JiangLibo JiangAlexandru JipaJay Hyun JoFilipe JoaquimWalker JohnsonBenjamin JonesRhiannon JonesNikola JovancevicMatthew JudahChang Kee JungThomas JunkYeon-Jae JwaMonireh KabirnezhadAsher KabothIgor KadenkoIgor KakorinAnastasia KalitkinaDaisy KalraOhannes Kamer KoseyanFelipe KamiyaDaniel KaplanGeorgia KaragiorgiGurkan KaramanArmin KarcherYannis KaryotakisSeiji KasaiS.P. KasettiLane KashurIoannis KatsioulasNarine KazaryanEdward KearnsPaul KeenerKevin KellyErnesto KempOtari KemulariaWes KetchumSteve KettellMarat KhabibullinAlexei KhotjantsevArsen KhvedelidzeDoojin KimBonnie KingBrian KirbyMike KirbyJoshua KleinJeffrey KleykampAnezka KlustovaThomas KobilarcikKevin KoehlerL.W. KoernerD.H. KohSam KohnPatrick KollerLiudmila KolupaevaDenis KorablevMike KordoskyThomas KoscUmut KoseV. Alan KosteleckyKunal KothekarIan KotlerVladimir KozhukalovRobert KralikLuke KreczkoFrank KrennrichIgor KresloWilliam KroppTereza KroupovaYury KudenkoVitaly KudryavtsevStephen KuhlmannSergey KulaginJason KumarPraveen KumarPablo KunzeRamachandra KuraviNadine KuritaChatura KuruppuVaclav KusThomas KutterJiri KvasnickaDonghyun KwakAndrew LambertBenjamin LandCharles LaneKarol LangThomas LangfordMark LangstaffFrancesco LanniOliver LantwinJacob LarkinPierre LasorakDavid LastAndy LaundrieGiuliano LaurentiAndrew LawrencePaul LaycockIonel LazanuMassimo LazzaroniTrung LeSara LeardiniJohn LearnedP. LebrunThomas LecompteClaire LeeZachary LeeVladyslav LeginGiovanna Lehmann MiottoRalf LehnertM.A. Leigui de OliveiraMatthaeus LeitnerL.M. LepinShirley W. LiYichen LiHeng-Ye LiaoCheng-Ju Stephen LinShih-Kai LinRoberto LinerosJiajie LingAdam ListerBryce LittlejohnJunze LiuYinrui LiuSarah LockwitzTimothy LoewMilos LokajicekIrakli LomidzeKen LongTom LordJohn M. LoseccoWilliam LouisXianguo LuKam-Biu LukBenjamin LundayXiao LuoEleonora LuppiThorsten LuxVitor LuzioJihane MaalmiDavid MacfarlaneAna Amelia MachadoPedro MachadoChristopher Thomas MaciasJolie R. MacierAntonello MaddalenaAlfonso MaderaPeter MadiganSteve MagillKendall MahnAmélia MaioAdryanna MajorKrishanu MajumdarJames MaloneyIgor MandrichenkoGianni MandrioliRoberto MandujanoJ.C. ManeiraLaura ManentiSteve ManlyAnthony MannKonstantinos ManolopoulosMaria Manrique PlataVenkata ManyamMiquel MarchanAlberto MarchionniWilliam MarcianoDanny MarfatiaCamillo MarianiJelena MaricicFranciole MarinhoAlysia MarinoThomas MarkiewiczDavid MarsdenMarvin MarshakChris MarshallJohn MarshallJacques MarteauJusto Martín-AlboNorman MartinezDavid Martinez CaicedoFrancisco Martínez LópezPablo Martínez MiravéSergey MartynenkoValerio MascagnaKatie MasonAndrew MastbaumFabrice MatichardShigenobu MatsunoJames MatthewsChristopher MaugerNicoletta MauriKonstantinos MavrokoridisIsobel MawbyRoberto MazzaAnna MazzacaneTracy McaskillElaine MccluskeyNicola McconkeyKevin McfarlandClark McgrewAndrew McnabAlexander MefodievPoonam MehtaPantelis MelasOlga MenaHector MendezPatricia MendezDiana MéndezA. MenegolliGuang MengMark MessierWilliam MetcalfMatthew MewesHolger MeyerTing MiaoGregory MichnaVeera MikolaRadovan MilincicGraham MillerWilliam MillerJoshua MillsOleg MineevAlessandro MinottiO.G. MirandaSandeep MiryalaC. Shekhar MishraSanjib R. MishraAaron MislivecMote MitchellDimitar MladenovIrina MocioiuKristian MoffatAndrew MoganNiccolo MoggiRukmani MohantaTanaz MohayaiNikolai MokhovJorge MolinaLaura Molina BuenoElisabetta MontagnaAlessandro MontanariClaudio MontanariDavid MontanariDaniele MontaninoL.M. Montaño ZetinaSeok Ho MoonMichael MooneyAlexandra MoorDeywis MorenoDavide MorettiCasandra MorrisChris MosseyMitchell MoteErdem MotukCélio MouraJoel MousseauGwenn MousterWei MuLeon MualemJustin MuellerMathew MuetherFranz MuheimAlan MuirMike MulhearnDonnie MunfordHajime MuramatsuMatt MurphySebastien MurphyJim MusserJane NachtmanYoshikazu NagaiSrishti NaguMikayel NalbandyanRaja NandakumarDonna NaplesShinya NaritaAtanu NathAnyssa Navrer-AgassonNitish NayakMiquel Nebot-GuinotKentaro NegishiJ.K. NelsonMatthew NelsonJake NesbitMarzio NessiDavid NewboldMitch NewcomerHannah NewtonRyan NicholFrancisco Nicolas-ArnaldosAdrian NikolicaJovana NikolovEvan NinerKurtis NishimuraAndrew NormanAnne NorrickPau NovellaJaroslaw NowakMichael OberlingJuan Pedro Ochoa-RicouxAndrew OlivierAlexander OlshevskiyYasar OnelYuriy OnishchukLuis Otiniano OrmacheaJordan OttLuca PaganiGuillermo PalacioOrnella PalamaraSandro PalestiniJonathan PaleyMarco PallaviciniCarmen PalomaresSupriya PanWilliam Panduro VazquezEmilija PanticVittorio PaoloneVaia PapadimitriouRiccardo PapaleoAntonis PapanestisSudarshan ParamesvaranStephen ParkeElisabetta ParozziSaba ParsaZohreh ParsaSabila ParveenMihaela ParvuDaniele PasciutoSilvia PascoliRamon PasetesLaura PasqualiniJaroslaw PasternakJoleen PaterCheryl PatrickLaura PatriziiR.B. PattersonSimon John PattonThomas PatzakAjib PaudelLaura PaulucciZarko PavlovicGreg PawloskiDavid PayneViktor PecSimon PeetersAldo Pena PerezElisabetta PennacchioAldo PenzoOrlando PeresCarlos PernasJames PerryDaniel PersheyGianluigi PessinaGianluca PetrilloCatia PettaRoberto PettiValerio PiaLuke PickeringFrancesco PietropaoloVinicius PimentelGiovanni PinaroliKomninos-John PlowsRobert PlunkettFederica PompaXavier PonsNavaneeth PoonthottathilFrancesco PoppiStephen PordesJoshua PorterSalvatore Davide PorzioMaxim PotekhinRenato PotenzaB.V. PotukuchiJuergen PozimskiMichele PozzatoSuprabh PrakashTarun PrakashChristian PrattMichela PrestFernanda PsihasDenis PugnereXin QianJennifer L. RaafVeljko RadekaJonas RademackerRadi RadevBalint RadicsAleena RafiqueEric RaguzinMousam RaiMiriama RajaoalisoaIgor RakhnoAndrianjafy Michaël RakotonandrasanaLaza RakotondravohitraRegina RameikaManuel Alejandro Ramirez DelgadoBryan RamsonA. RappoldiG.L. RaselliPeter RatoffSanil RautHerilala RazafinimeRado Fanantenana RazakamiandraE.M. ReaJ.S. RealBrian RebelRonald RechenmacherMarina Reggiani-GuzzoJuergen ReichenbacherS.D. ReitznerHaifa Rejeb SfarAndrew RenshawSergio ResciaFilippo ResnatiMarlos RibasStefano RiboldiCiro RiccioGiorgio RiccobeneLogan RiceJean-Stéphane RicolAlberto RigamontiYann-Axel RigautEdgar RincónAsher Ritchie-YatesDavid RiveraRyan RiveraArnaud RobertJose Luis Rocabado RochaLeon RochesterMarco RodaPhilip RodriguesManuel Rodriguez AlonsoJairo Rodriguez RondonEmanuele RomeoSalvador Rosauro-AlcarazPhilippe RosierMassimo RossellaMarco RossiMark Ross-LonerganJogesh RoutPalash RoyAndre RubbiaCarlo RubbiaBrooke RussellDaniel RuterboriesArseniy RybnikovAngela Saa-HernandezRuben SaakyanSabrina SacerdotiNarendra SahuPaola SalaNicholas SamiosOleg SamoylovMayly SanchezVern SandbergDavid SandersDavid SankeyDanilo SantoroNiki SaoulidouPiera SapienzaCarlos SarastyIna SarcevicGeoffrey SavageVladimir SavinovGiacomo ScanaviniAlberto ScaramelliAndrew ScarffAndrea ScarpelliTristan SchefkeHeidi SchellmanSebastiano SchifanoPhilip SchlabachDavid SchmitzAustin SchneiderKate ScholbergAnne SchukraftEttore SegretoAlexander SelyuninCarlos SeniseJon SensenigDavide SgalabernaMichael H. ShaevitzSheeba ShafaqFady ShakerMichael ShammaPeter ShanahanRalitsa SharankovaH.R. SharmaR. SharmaR.K. SharmaKate ShawTerri ShawKonstantin ShchabloClaire Shepherd-ThemistocleousAndrey SheshukovWei ShiSeodong ShinIan ShoemakerDean ShooltzRobert ShrockJoseph SilberLaurent SimardFrank SimonJames SinclairGleb SinevJaydip SinghJyotsna SinghLakwinder SinghPrabhjot SinghVenktesh SinghSushil Singh ChauhanRoland SiposGabriele SirriAndriaseta SitrakaKim SiyeonKnut SkarpaasErica SmithPaul SmithJan SmolikMichael SmyE.L. SniderPavel SnopokDaniel Snowden-IfftMônica Soares NunesHenry SobelMitch SoderbergSergei SokolovCarlos Solano SalinasStefan Söldner-RemboldStefano Roberto SoletiNicholas SolomeyVladimir SolovovWalter SondheimMichel SorelAlbert SotnikovJose Soto-OtonAlexandre SousaKarel SoustruznikFabio SpagliardiMaura SpanuJoshua SpitzN.J. SpoonerKyle SpurgeonDeigo StalderMichelle StancariLuca StancoJacob SteenisRaul SteinHerbert M. SteinerAndré Steklain LisbôaAnna StepanovaJames StewartBen StillwellJason StockFrancesca StockerTyler StokesMatthew StraitThomas StraussLouis StrigariAlexander StuartJ.G. SuarezJoeal SubashAntonio SurdoVasja SusicLouise SuterConcetta Maria SuteraYury SuvorovRobert SvobodaBarbara SzczerbinskaAndrzej SzelcNibir TalukdarJose TamaraHirohisa TanakaShaochun TangBeatriz Tapia OreguiAlexander TapperSalman TariqEaglekumar TarparaNeeraj TataE. TatarRex TayloeAbraham Meles TekluPeter TennessenMatteo TentiKazuhiro TeraoFrancesco TerranovaGemma TesteraTarak ThakoreAlessandro TheaAdrian ThompsonCraig ThornSteven C. TimmVladimir TishchenkoNataša TodorovićLuca TomassettiAlessandra TonazzoDmitri TorbunovMarta TortiMariam TortolaFrancesco TortoriciNicolo TosiDante TotaniMatthew ToupsChristos TouramanisRiccardo TravagliniJason TrevorStoyan TrilovWladyslaw TrzaskaYu-Dai TsaiYun-Tse TsaiZviadi TsamalaidzeKa Vang TsangNikolozi TsveravaSerhan TufanliCraig TullJessica TurnerJennifer TylerE. TyleyMartin TzanovLorenzo UboldiMelissa UchidaJon UrheimTracy UsherHilary UtaegbulamSergey UzunyanM.R. VaginsPatricia VahleSammy ValderGustavo ValdiviessoEdgar ValenciaRodolfo ValentimZoya VallariErik VallazzaJ.W. ValleSofia VallecorsaRick van BergRichard van de WaterDavid Vanegas ForeroDavid VanneromFilippo VaraniniDanaisis Vargas OlivaGary VarnerSvetlana VasinaNoah VaughanKamran VaziriJuan VegaSandro VenturaAntonio VerdugoStefano VerganiM.A. VermeulenMarco VerzocchiMatteo VicenziHenrique Vieira de SouzaChiara VignoliCristovao VilelaBrett VirenTomas VrbaQuynh VuongTomasz WachalaAlexander WagnerAbigail WaldronMichael WallbankTammy WaltonHanguo WangJingbo WangL. WangMichael WangXiaoran WangY. WangY. WangKarl WarburtonDavid WarnerMorgan WasckoDavid WatersAlan WatsonKlaudia WawrowskaPierce WeatherlyAlfons WeberMichele WeberHanyu WeiAmanda WeinsteinDan WenmanMatthew WetsteinJames WhilhelmiA. WhiteA. WhiteBrandon WhiteStephen WhiteLeigh WhiteheadDenver WhittingtonMichael WilkingAlexander WilkinsonCallum WilkinsonZachary WilliamsFergus WilsonRobert WilsonWilliam WisniewskiJeremy WolcottJean WolfsTaritree WongjiradAnthony WoodKevin WoodElizabeth WorcesterMatthew WorcesterMarianette WospakrikKarolina WresiloClarence WretShaowei WuWanwei WuWenjie WuYiwen XiaoIoannis XiotidisBarbara YaeggyErin YandelGuang YangKang YangTingjun YangAlejandro YankelevichNikolai YershovKatsuya YoneharaYoung Soo YoonTim YoungB. YuH. YuH. YuJae YuYiding YuWenlong YuanRowan ZakiJaroslav ZalesakLaura ZambelliBruno ZamoranoAndrea ZaniLuis ZazuetaGeralyn ZellerJoseph ZennamoKyle ZeugChao ZhangShuaixiang ZhangYuze ZhangManhong ZhaoElena ZhivunE.D. ZimmermanStefano ZucchelliJosef ZuklinVishnu ZutshiRobert Zwaska
• Organismes : Laboratoire d'Annecy de Physique des Particules Institut de Physique des 2 Infinis de Lyon Institut de Physique des 2 Infinis de Lyon Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Physique des 2 Infinis de Lyon Institut de Physique des 2 Infinis de Lyon Laboratoire de l'Accélérateur Linéaire AstroParticule et Cosmologie AstroParticule et Cosmologie Laboratoire de Physique Subatomique et de Cosmologie AstroParticule et Cosmologie Institut de Physique des 2 Infinis de Lyon AstroParticule et Cosmologie Laboratoire d'Annecy de Physique des Particules Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire d'Annecy de Physique des Particules Laboratoire de l'Accélérateur Linéaire Institut de Physique des 2 Infinis de Lyon Laboratoire d'Annecy de Physique des Particules Institut de Physique des 2 Infinis de Lyon Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire de l'Accélérateur Linéaire Laboratoire d'Annecy de Physique des Particules Laboratoire de Physique Subatomique et de Cosmologie Laboratoire d'Annecy de Physique des Particules Laboratoire d'Annecy de Physique des Particules Institut de Physique des 2 Infinis de Lyon Laboratoire de l'Accélérateur Linéaire Institut de Physique des 2 Infinis de Lyon AstroParticule et Cosmologie Institut de Physique des 2 Infinis de Lyon Institut de Physique des 2 Infinis de Lyon Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de l'Accélérateur Linéaire Laboratoire de l'Accélérateur Linéaire AstroParticule et Cosmologie Institut de Physique des 2 Infinis de Lyon Laboratoire de l'Accélérateur Linéaire AstroParticule et Cosmologie AstroParticule et Cosmologie Laboratoire d'Annecy de Physique des Particules

---

Résumé : This document describes Offline Software and Computing for the Deep Underground Neutrino Experiment (DUNE) experiment, in particular, the conceptual design of the offline computing needed to accomplish its physics goals. Our emphasis in this document is the development of the computing infrastructure needed to acquire, catalog, reconstruct, simulate and analyze the data from the DUNE experiment and its prototypes. In this effort, we concentrate on developing the tools and systems that facilitate the development and deployment of advanced algorithms. Rather than prescribing particular algorithms, our goal is to provide resources that are flexible and accessible enough to support creative software solutions as HEP computing evolves and to provide computing that achieves the physics goals of the DUNE experiment.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2022
• Auteurs : Adrien GrancherLudivine BeaussireSylvain ManfrediKarine Le MalicotMarie DutherageVincent VerdierClaire MulotOlivier BouchéJean-Marc PhélipCharles-Briac LevachéPhilippe DeguiralSophie CoutantDavid SefriouiJean-François EmilePierre Laurent-PuigFrédéric BibeauPierre MichelNasrin Sarafan-VasseurCôme LepageFrederic Di Fiore
• Organismes : Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Lipides - Nutrition - Cancer [Dijon - U1231] Lipides - Nutrition - Cancer [Dijon - U1231] Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Epigenetec Université de Reims Champagne-Ardenne Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Clinique Francheville [Périgueux] Centre hospitalier de Saint-Nazaire Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Hôpital Ambroise Paré [AP-HP] Hôpital Européen Georges Pompidou [APHP] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Lipides - Nutrition - Cancer [Dijon - U1231] Cancer and Brain Genomics CHU Rouen
• Publié dans Frontiers in Oncology le 26/10/2020

---

Résumé : Circulating tumor DNA (ctDNA) is reported to be promising in localized colorectal cancer (CRC). The present study aimed to retrospectively evaluate the impact of ctDNA in patients with a resected stage II CRC from the PROGIGE 13 trial with available paired tumor and blood samples. A group of recurrent patients were matched one-to-one with nonrecurrent patients according to sex, tumor location, treatment sequence, and blood collection timing. CtDNA was analyzed by digital PCR according to NGS of tumors. Disease-free survival (DFS) and overall survival (OS) were analyzed based on ctDNA, and the risks of recurrence and death were determined. A total of 134 patients were included, with 67 patients in each group. At least one alteration was identified in 115/134 tumors. Postoperative ctDNA was detected in 10/111 (9.0%) informative samples and was detected more frequently in the recurrent group (16.7% versus 1.8%; p = 0.02). The median DFS of ctDNA+ versus ctDNA- patients was 16.8 versus 54 months (p = 0.002), respectively, and the median OS was 51.3 versus 69.5 months (p = 0.03), respectively. CtDNA was associated with recurrence (ORa = 11.13, p = 0.03) and death (HRa = 3.15, p = 0.01). In conclusion, the presence of postoperative ctDNA is associated with both recurrence and survival in stage II CRC.

---

Fichiers liés : fonc-12-973167.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2022
• Auteurs : Romain TortuyauxFrédéric WalletPhilippe DerambureSaad Nseir
• Organismes : Centre Hospitalier Régional Universitaire [CHU Lille] Institut Pasteur de Lille Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576
• Publié dans Journal of Clinical Medicine le 29/10/2020

---

Résumé : Suspicion of bacterial aspiration pneumonia (BAP) is frequent during generalized convulsive status epilepticus (GCSE). Early identification of BAP is required in order to avoid useless antibiotic therapy. In this retrospective monocentric study, we aimed to determine the incidence of aspiration syndrome and BAP in GCSE requiring mechanical ventilation (MV) and factors associated with the occurrence of BAP. Patients were older than 18 years and had GCSE requiring MV. To distinguish BAP from pneumonitis, tracheal aspirate and quantitative microbiological criterion were used. Out of 226 consecutive patients, 103 patients (46%) had an aspiration syndrome, including 54 (52%) with a BAP. Staphylococcus aureus represented 33% of bacterial strains. No relevant baseline characteristics differed, including serum levels of CRP, PCT, and albumin. The median duration of treatment for BAP was 7 days (5–7). Patients with BAP did not have a longer duration of MV (p = 0.18) and ICU stay (p = 0.18) than those with pneumonitis. At 3 months, 24 patients (44%) with BAP and 10 (27%) with pneumonitis had a poor functional outcome (p = 0.06). In conclusion, among patients with GCSE, half of the patients had an aspiration syndrome and one-quarter suffered from BAP. Clinical characteristics and biomarkers were not useful for differentiating BAP from pneumonitis. These results highlight the need for a method to rapidly differentiate BAP from pneumonitis, such as polymerase-chain-reaction-based techniques.

---

Fichiers liés : P22.62 jcm-11-06673-v2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/11/2022
• Auteurs : Markus SchlaichMarc BelletBarthelemy von HallerParisa DanaietashGeorge BakrisJohn FlackRoland DreierMouna Sassi-SayadiLloyd HaskellKrzysztof NarkiewiczJi-Guang WangChristopher ReidMarkus SchlaichIvor KatzAndrew AjaniSinjini BiswasMurray EslerGrahame ElderSimon RogerDavid ColquhounJohn MooneyTine de BackerAlexandre PersuMartin ChaumontJean-Marie KrzesinskiThomas VanabscheGinette GirardLew PliammErnesto SchiffrinFatima MeraliGeorge DresserMichel ValleeShivinder JollyStephen ChowJiguang WangJianjun MuJing YuHong YuanYingqing FengXin ZhangJianhong XieLing LinMiroslav SoucekJiri WidimskyRenata CifkovaJan VaclavikMartin UllrychMartin LukacIvan RychlikThomas Guldager LauridsenIlkka KantolaJyrki TaurioOlavi UkkolaOlivier OrmezzanoPhilippe GosseMichel AziziPierre-Yves CourandPascal DelsartJean Michel TartiereFelix MahfoudRoland SchmiederJohannes StegbauerPhilipp LurzMichael KoziolekChristian OttNicole ToursarkissianKonstantinos TsioufisKonstantinos KyfnidisAthanasios ManolisSotirios PatsilinakosPantelis ZebekakisApostolos KaravidasPall DenesKatalin BezzeghMarianna ZsomLaszlo KovacsYehonatan SharabiMazen EliasIvetta SukholutskyChaim YosefyIrina KenisShaul AtarMassimo VolpeMuiesan Maria LorenzaStefano TaddeiGuido GrassiFranco VeglioJung Woo SonJang-Young KimJoong-Il ParkChang Hoon LeeHae-Young LeeRasa RaugalieneJolanta Elena MarcinkevicieneRoma KavaliauskieneJaap DeinumAbraham KroonBert-Jan van den BornAndrzej JanuszewiczAndrzej TykarskiJolanta WalczewskaZbigniew GaciongAndrzej WiecekMarzena ChrostowskaAndrzej KleinrokJan KrekoraGrzegorz KaniaAnna Podrazka-SzczepaniakCezary GolawskiMaciej PodziewskiBarbara KaczmarekGrzegorz SkoczylasAndrzej WilkolaskiIwona WozniakMarzena Janik-PalazzoloBarbara RewerskaAlexandra KonradiYuriy ShvartsTamara PecherinaKonstantin NikolaevGapon LiudmilaOlga OrlikovaViktor MordovinNatalia PetrochenkovaGadel KamalovElena KosmachevaKonstantin NikolaevVadim TyrenkoVladimir GorbunovAndrey ObrezanTatiana SupryadkinaIrina LerOleg KotenkoAnatoly KuzinFernando MartinezJosep RedonAnna OliverasLuis Beltran RomeroValerii ShatyloLeonid RudenkoAndriiy BazylevychYurii RudykOleksandr KarpenkoMykola StanislavchukVira TseluykoMykola KushnirErvin AsanovYuriy SirenkoAndriy YagenskyDavid CollierPankaj GuptaDavid WebbMary MacleodJames MclayAaron PeaceSamir AroraPatricia BuchananRobert HarrisRonald DegarmoMario GuillenAdam KarnsJoel NeutelYogesh PaliwalKarlton PettisPhillip TothJeffrey WayneBain ButcherPhillip DillerSuzanne OparilDavid CalhounDonald BrautigamJohn FlackJesse GoldmanArash RashidiNabeel AslamWilliam HaleyNabil AndrawisBrian LangRandy MillerJames PowellRobert DewhurstJames PritchardDinesh KhannaDennis TangNashwa GabraJean ParkConigliaro JonesCranford ScottBlanca LunaMurtaza MussajiRavi BhagwatMichael BauerJohn McgintyRajesh NambiarRenee SangrigoliWilliam Ross DavisWilliam EavesFrank McgrewAhmed AwadEric BolsterDavid ScottParamjit KaliraoPascal DabelWesley CalhounSteven GougeMark WarrenMary Katherine LawrenceAamir JamalMohamed El-ShahawyCarlos MercadoJayant KumarPedro Velasquez-MieyerRobert BuschTodd LewisLisa Rich
• Organismes : The University of Western Australia Baker Heart and Diabetes Institute (AUSTRALIA) State University of New York University of Chicago Biozentrum [Basel, Suisse] Medical University of Gdańsk Ruijin Hospital [Shanghai, Chine] University of Melbourne The University of Western Australia Baker Heart and Diabetes Institute (AUSTRALIA) Human Neurotransmitter Laboratory Imagerie Ultrasonore
• Publié dans The Lancet le 02/11/2020

---

Résumé : Background Resistant hypertension is associated with increased cardiovascular risk. The endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently not targeted therapeutically, thereby leaving this relevant pathophysiological pathway unopposed with currently available drugs. The aim of the study was to assess the blood pressure lowering efficacy of the dual endothelin antagonist aprocitentan in patients with resistant hypertension. Methods PRECISION was a multicentre, blinded, randomised, parallel-group, phase 3 study, which was done in hospitals or research centres in Europe, North America, Asia, and Australia. Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: part 1 was the 4-week double-blind, randomised, and placebo-controlled part, in which patients received aprocitentan 12•5 mg, aprocitentan 25 mg, or placebo in a 1:1:1 ratio; part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg; and part 3 was a 12-week double-blind, randomised, and placebo-controlled withdrawal part, in which patients were re-randomised to aprocitentan 25 mg or placebo in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes. The study is registered on ClinicalTrials.gov, NCT03541174. Findings The PRECISION study was done from June 18, 2018, to April 25, 2022. 1965 individuals were screened and 730 were randomly assigned. Of these 730 patients, 704 (96%) completed part 1 of the study; of these, 613 (87%) completed part 2 and, of these, 577 (94%) completed part 3 of the study. The least square mean (SE) change in office systolic blood pressure at 4 weeks was-15•3 (SE 0•9) mm Hg for aprocitentan 12•5 mg,-15•2 (0•9) mm Hg for aprocitentan 25 mg, and-11•5 (0•9) mm Hg for placebo, for a difference versus placebo of-3•8 (1•3) mm Hg (97•5% CI-6•8 to-0•8, p=0•0042) and-3•7 (1•3) mm Hg (-6•7 to-0•8; p=0•0046), respectively. The respective difference for 24 h ambulatory systolic blood pressure was-4•2 mm Hg (95% CI-6•2 to-2•1) and-5•9 mm Hg (-7•9 to-3•8). After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5•8 mm Hg, 95% CI 3•7 to 7•9, p<0•0001). The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12•5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively. This event led to discontinuation in seven patients treated with aprocitentan. During the trial, a total of 11 treatment-emergent deaths occurred, none of which were regarded by the investigators to be related to study treatment. Interpretation In patients with resistant hypertension, aprocitentan was well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40.

---

Fichiers liés : 1-s2.0-S0140673622020347-main.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 06/11/2022
• Auteurs : Anne-Marie BaconNicolas BourgonElise DufourFabrice DemeterClément ZanolliKira E WestawayRenaud Joannes-BoyauPhilippe DuringerJean-Luc PoncheMike W MorleyEric SuzzoniSébastien FrangeulQuentin BoeschPierre-Olivier AntoineSouliphane BoualaphanePhonephanh SichanthongtipDaovee SihanamThi Mai NguyenAnh NguyenDenis FiorilloOlivier TombretElise Patole-EdoumbaTyler E DunnAlexandra ZachwiejaThonglith LuangkhothViengkeo SouksavatdyThongsa SayavongkhamdyLaura ShackelfordJean- Jacques Hublin
• Organismes : Biologie, anthropologie, biométrie, épigénétique, lignées : De la diversité des populations à l'individu, de l'identification à l'identité Ecole et Observatoire des Sciences de la Terre Laboratoire Image, Ville, Environnement Ecole et Observatoire des Sciences de la Terre

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/11/2022
• Auteurs : Nicholas FuggleNasser Al-DaghriOlivier BockJaime BrancoOlivier BruyèreEnrique CasadoEtienne CavalierBernard CortetMaarten de WitAndrea GiustiPhilippe HalboutNicholas HarveyMickaël HiligsmannJean-Marc KaufmanAndreas KurthStefania MaggiRadmila MatijevicSalvatore MinisolaSantiago PalaciosRégis Pierre RadermeckerFriederike ThomasiusSansin TuzunNicola VeroneseJohn KanisJean-Yves ReginsterRené RizzoliCyrus Cooper
• Organismes : Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
• Publié dans Aging Clinical and Experimental Research le 27/10/2020

---

Résumé : Abstract Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes.

---

Source